Dechra Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 1/6

Dechra Pharmaceuticals ha un patrimonio netto totale di £755.2M e un debito totale di £487.6M, che porta il suo rapporto debito/patrimonio netto a 64.6%. Le sue attività totali e le sue passività totali sono rispettivamente £1.6B e £814.2M. L'EBIT di Dechra Pharmaceuticals è £17.1M rendendo il suo rapporto di copertura degli interessi 0.8. Ha liquidità e investimenti a breve termine pari a £74.4M.

Informazioni chiave

64.6%

Rapporto debito/patrimonio netto

UK£487.60m

Debito

Indice di copertura degli interessi	0.8x
Contanti	UK£74.40m
Patrimonio netto	UK£755.20m
Totale passività	UK£814.20m
Totale attività	UK£1.57b

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( £467.9M ) di DPHL superano le sue passività a breve termine ( £164.0M ).

Passività a lungo termine: Le attività a breve termine di DPHL ( £467.9M ) non coprono le sue passività a lungo termine ( £650.2M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 54.7% ) di DPHL è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di DPHL è aumentato da 57.6% a 64.6% negli ultimi 5 anni.

Copertura del debito: Il debito di DPHL non è ben coperto dal flusso di cassa operativo ( 13% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di DPHL non sono ben coperti dall'EBIT ( 0.8 x copertura).

Dechra Pharmaceuticals Salute del bilancio

Salute finanziaria criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Intends to Delist from Official List

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Now 21% undervalued after recent price drop

Less than half of directors are independent

Upcoming dividend of UK£0.33 per share

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Full year 2022 earnings released: EPS: UK£0.54 (vs UK£0.51 in FY 2021)

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Now 21% undervalued after recent price drop

Dechra Pharmaceuticals PLC Announces Executive Changes

Less than half of directors are independent

Non-Executive Chairman recently bought UK£99k worth of stock

Upcoming dividend of UK£0.12 per share

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Upcoming dividend of UK£0.29 per share

Board Member recently sold UK£875k worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Board Member recently sold UK£963k worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

New 90-day high: UK£37.50

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

New 90-day high: UK£35.98

Dechra Pharmaceuticals PLC Launches Mirataz

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane